Immunoglobulin E–Mediated Severe Allergy to Hyoscine Butylbromide

Mendez Diaz Y1, Gómez Torrijos E1, Moreno Lozano L1, Extremera Ortega AM1, García Rodríguez R1, Hornos López MC2, Pineda de la Rosa F3, Borja Segade J1

1Allergology Service, Hospital General Universitario, Ciudad Real, Spain
2Intensive Care Unit, Hospital General Universitario, Ciudad Real, Spain
3Diater Laboratory, Leganés, Spain

doi: 10.18176/jiaci.0247

Keywords: Hyoscine butylbromide. Kounis syndrome. Allergy. Anaphylactic reaction. IgE–mediated hypersensitivity.

Hyoscine butylbromide is an antispasmodic cholinergic agent with a quaternary ammonium structure [1]. Kounis syndrome (KS) is an acute coronary syndrome during an allergic anaphylactic reaction. It is classified into 3 variants [2]:

- Type I, without coronary heart disease, in which the allergic reaction leads to coronary vasospasm.
- Type II, with coronary disease, in which the acute release of mediators leads to the rupture of a preexisting atheromatous plaque.
- Type III, in which the allergic event leads to pharmacooactive stent thrombosis.

A 51-year-old man received 20 mg of hyoscine butylbromide, 2 g of metamizole, 10 mg of metoclopramide, and 40 mg of pantoprazole for biliary colic. Ten minutes after endovenous administration of the drugs, the patient complained of epigastric pain, sweating, sickness, and vomiting and presented loss of consciousness, hypotension (58/30 mmHg), ST-segment elevation on the inferior heart wall, and cardiorespiratory arrest. No skin symptoms were observed. After being stabilized, the patient was admitted to the intensive care unit (ICU) for orotracheal intubation and mechanical ventilation. Owing to the persistence of abdominal pain a further dose of 20 mg of hyoscine butylbromide was administered; macular exanthema appeared immediately on the face and trunk.

The ECG performed in the emergency room showed a 5-mm ST-segment elevation on the inferior heart wall and a decreased ST-segment in V2-V3, I, and aVL. Serum troponin was elevated (0.54 ng/mL). Twenty-four hours after admission, ECG abnormalities had resolved and troponin levels returned to normal values.

All the cardiological tests performed showed normal results. Contractility alterations were not found in echocardiography, the thoracic CT angiogram ruled out acute aortic syndrome, and coronary angiography showed normal coronary arteries.

The allergology study revealed the following results: positive skin prick test (SPT) to hyoscine butylbromide at 20 mg/mL (5×3-mm papule diameter) and negative at 0.4 g/mL to metamizole. SPT with hyoscine butylbromide was performed in 3 atopic and nonatopic patients, with negative results. Histamine phosphate (10 mg/mL) (5×7 mm) was used as a positive control and saline (0.9%) as a negative control.

Intradermal tests (ID) with 1/100 metamizole and 1/10 metamizole were negative.

The patient refused to undergo challenge with metamizole. The results of challenge tests (CT) with pantoprazole and metoclopramide were negative.

The eosinophil count in peripheral blood was normal (110 eosinophils/µL), as was basal serum tryptase (4.5 µg/L). Specific IgE to hyoscine butylbromide could not be determined, because the test is not commercially available.

The basophil activation tests (BAT) with hyoscine butylbromide at 1/100, 1/10, and undiluted were negative.

Passive sensitization with hyoscine butylbromide 20 mg/mL in the histamine release test was positive (10 ng/mL of histamine released 10%) (Figure).

KS can manifest as coronary spasms, acute myocardial infarction, or stent thrombosis. Although this clinical entity is well-documented, there are many unanswered questions regarding its etiology, pathophysiology, and treatment [3]. In addition, while not rare, KS is infrequently diagnosed [4].

Diagnosis is based on symptoms and suggestive signs of an acute allergic reaction simultaneously with acute coronary syndrome (angina, vegetative symptoms) related to previous contact with a possible allergen [4,5]. The patient we report, who had no coronary risk factors, had presented 2 episodes of epigastric pain with bilious vomiting during the previous 6 months. On those occasions, ECG did not reveal myocardial ischemia, and serum troponin was within the normal range. The diagnosis was uncomplicated biliary colic. At the last visit for abdominal pain, empirical analgesic treatment was started after an ECG performed to rule out cardiac angina in the emergency department before drug infusion.

Therefore, the sudden onset of symptoms of acute coronary syndrome and ST-segment elevation associated with increased troponins after treatment with various drugs, together with an echocardiogram with no contractility alterations, led us to suspect type I KS.

In the absence of a commercial test to determine specific IgE to hyoscine butylbromide, a dot-blot was performed with the patient’s serum against hyoscine butylbromide and metamizole, although the results were negative. In the release of histamine via passive immunization, specific IgE binds to the IgE receptor of the healthy donor basophil. After stimulation with the reagents, histamine release was significant and probably IgE-mediated [6]. Given these results, the positive skin test with hyoscine butylbromide, the positive reexposure with hyoscine butylbromide in the intensive care unit, and the histamine release test result, we considered that hyoscine butylbromide was the most probable culprit drug, with a high probability of an IgE-mediated mechanism. The normal basal tryptase levels ruled out mast cell activation syndrome [7].
Reexposure to hyoscine butylbromide in the intensive care unit was performed 24 hours after onset of the clinical picture, when the patient was receiving vasoactive drugs. The infusion of hyoscine butylbromide was not completed because of cutaneous exanthema. Therefore, it does not seem likely that a new episode of anaphylaxis and acute coronary syndrome was triggered.

We cannot exclude hypersensitivity to metamizole as the main etiology of KS owing to the absence of a CT scan (gold standard test). Similarly, we cannot exclude the possibility of further exanthema due to sensitization to hyoscine butylbromide (double sensitization).

Although hyoscine butylbromide is widely used, very few associated hypersensitivity reactions have been reported. González-Mendiola et al [8] reported a case of urticaria with positive skin and challenge tests to hyoscine butylbromide. Thirty years ago, another possible reaction manifesting only with bronchospasm was attributed to hyoscine butylbromide, although the patient did not undergo allergy testing. Angioedema and urticaria have been reported in a patient treated with hyoscine butylbromide; the authors suggested an IgE-mediated mechanism based on the patient's symptoms, although they did not perform an allergy study [9]. A case of sudden death due to intramuscular hyoscine butylbromide was reported in a patient with significant elevated serum tryptase (100 mg/L), thus indicating that death was due to type I allergy to this drug [10].

We report the first case of severe type I KS probably caused by an IgE-mediated hypersensitivity reaction to hyoscine butylbromide.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin

Sequeira T 1, Gaspar 2, Mota I 2, Correia M 2, Chambel M 2, Morais-Almeida M2

1 Pulmonology Department, Prof. Doutor Fernando Fonseca Hospital, Lisbon, Portugal
2 Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal


Key words: Kounis syndrome. Anaphylaxis. Cefazolin. First-generation cephalosporin.


Kounis syndrome (KS) was first described in 1991 by Kounis and Zavras [1]. The syndrome is characterized by the simultaneous presence of anaphylactic and cardiac events [1]. KS is also known as allergic angina or allergic myocardial infarction. It is thought that following an allergic stimulus, inflammatory mediators are released by mast cells, leading to spastic contraction of coronary smooth muscle cells [2,3]. Three types of KS have been described [4], as follows: type I, coronary vasospasm without significant coronary disease; type II, patients with pre-existing coronary disease in which the release of pro-inflammatory mediators (histamine, leukotrienes and serotonin) can cause vasospasm or instability of atherosclerotic plaques; and type III, in which drug-eluting stent thrombosis is associated with a hypersensitivity reaction [5]. Although several drugs (antibiotics, nonsteroidal anti-inflammatory drugs, anticoagulants, corticosteroids, anesthetics, and contrast media) have been associated with KS, antibiotics are the most frequently involved [6,7]. Recently, Renda et al [8] identified the largest case series on KS associated with antibiotics, with 37.5% of all cases involving amoxicillin/clavulanic acid (6 cases) and the remaining 10 cases caused by amoxicillin alone, piperacillin/tazobactam, ceftriaxone, cefazolin, levofloxacin, and metronidazole.

We report the case of a 56-year-old man who developed KS immediately after intravenous administration of cefazolin. To the best of our knowledge, this is the first case of KS with selective anaphylaxis to cefazolin. Sánchez et al [9] reported type I KS due to rocuronium and/or cefazolin with positive skin test results to both drugs, although, given that the authors did not present any further data (skin test with the remaining ß-lactams or drug provocation tests), we cannot consider this case to be clearly selective or even caused only by cefazolin.

The patient had a medical history of dyslipidemia and no personal history of allergy, although he did have a family history of drug allergy (brother with a history of penicillin allergy). He underwent knee arthroscopy (for meniscus tear), with no complications during the procedure. He was always kept under

Manuscript received September 7, 2017; accepted for publication February 27, 2018.

Elisa Gomez Torrijos
Hospital General Universitario de Ciudad Real
C/ Obispo Rafael Torija s/n
13005 Ciudad Real, Spain
E-mail: egomezr.cr@gmail.com
jmborjaseg@gmail.com

References: